Free/total prostate-specific antigen ratio can prevent unnecessary prostate biopsies

Urology

Volumn 52, Issue 3, 1998, Pages 479-486

  Trinkler, Felix B ^a   Schmid, Daniel M ^a   Hauri, Dieter ^a   Pei, Patric ^a   Maly, Friedrich E ^a   Sulser, Tullio ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; BIOPSY; DECISION TREES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; SENSITIVITY AND SPECIFICITY;

EID: 0032168446     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00157-5     Document Type: Article

References (28)

1. 1. McCormack RT, Rittenhouse HG, Finalay JA, et al: Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new area. Urology 45: 729-744, 1995.
2. 2. Kamoshida S, and Tsutsumi Y: Extraprostatic localization of prostatic acid phosphatase and prostate-specific antigen: distribution of cloacogenic glandular epithelium and sex dependent expression in human anal gland. Hum Pathol 21: 1108-1111, 1990.
3. 3. Yu H, Diamandis EP, Monne M, et al: Oral contraceptive-induced expression of prostate-specific antigen in the female breast. J Biol Chem 270: 6615-6618, 1995.
4. 4. Yu H, Diamantis EP, and Sutherland DJ: Immunoreactive prostate-specific antigen level in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem 27: 75-79, 1994.
5. 5. Benson MC, Whang IS, Pantuck A, et al: Prostate specific antigen density: a means of distinguishing between benign prostatic hypertrophy and prostate cancer. J Urol 147(3 pt2): 815-816, 1992.
6. 6. Carter HB, Morrell CH, Persons JD, et al: Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res 52: 3323-3328, 1992.
7. 7. Schmid HP, McNeal JE, and Stamey TA: Observation on the doubling time of prostate cancer. Cancer 71: 2031-2040, 1993.
8. 8. Oesterling JE, Cooner WH, Jacobson SJ, et al: Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 270: 860-864, 1993.
9. 9. DeAntoni EP, Crawford ED, Oesterling JE, et al: Age-and race-specific reference ranges for prostate-specific antigen from a large community-based study. Urology 48: 234-239, 1996.
10. 10. Cheryl TL, and Oesterling JE: Diagnostic markers of prostate cancer: utility of prostate-specific antigen in diagnosis and staging. Semin Surg Oncol 11: 23-35, 1995.
11. 11. Partin AW, and Oesterling JE: Prostate-specific antigen in clinical urologic practice. AUA Update Series 14(1): 1-11, 1995.
12. 12. Brawer MK, Aramburu EAG, Chen GL, et al: The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostate carcinoma. J Urol 150: 369-373, 1993.
13. 13. Christensson A, Laurell CB, and Lilja H: Enzymatic activity of the prostate-specific antigen and its reaction with extracellular serin protease inhibitors. Eur J Biochem 194: 755-763, 1990.
14. 14. Stenman UH, Leinonen J, Alfthan H, et al: A complex between prostate-specific antigen and α1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51: 222-226, 1991.
15. 15. Hilz H: Molekulare Formen des PSA und ihre klinische Signifikanz. Urologe (A) 34: 275-282, 1995.
16. 16. Bjartell A, Bjork T, Matikainen MT, et al: Production of alpha-1-antichymotrypsin by PSA-containing cells of human prostate epithelium. Urology 42: 502-510, 1993.
17. 17. Marley GM, Miller MC, Kattan MW, et al: Free and complexed prostate-specific antigen ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia. Urology 48: 16-22, 1996.
18. 18. Reissigl A, Klocker H, Pointer J, et al: Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening. Urology 48: 62-66, 1996.
19. 19. Björk TH, Piironen T, Petterson K, et al: Comparison of analysis of different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer. Urology 48: 882-888, 1996.
20. 20. Roehrborn CG, Gregory A, McConnell JD, et al: Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology. Urology 48: 23-32, 1996.
21. 21. Catalona WJ, Smith DS, Wolfert PD, et al: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274: 1214-1220, 1995.
22. 22. Vashi AR, Wojno KJ, Henricks WH, et al: Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology 49: 19-27, 1997.
23. 23. Semjonow A, Oberpfenning F, Brandt B, et al: Impact of free prostate-specific antigen on discordant measurement results of assay for total prostate-specific antigen. Urology 48: 10-15, 1996.
24. 24. Semjonow A, Brandt B, Oberpenning F, et al: Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen levels. Prostate Suppl 7: 3-16, 1996.
25. 25. Stamey TA: Second Stanford conference on international standardization of prostate-specific antigen immunoassays: September 1 and 2, 1994. Urology 45: 173-184, 1995.
26. 26. Prestigiacomo AF, and Stamey TA: Can free and total prostate specific antigen and prostatic volume distinguish between men with negative and positive systematic ultrasound guided prostate biopsies? J Urol 157: 189-194, 1997.
27. 27. Thiel RP, Oesterling JE, Wojno KJ, et al: Multicenter comparison of diagnostic performance of free prostate-specific antigen. Urology 48: 45-50, 1996.
28. 28. Arcangeli CG, Shepherd DL, Smith DS, et al: Correlation of percent free-PSA with pathologic features of prostatic carcinomas (abstract). J Urol 155(suppl): 415A, 1996.